DAUNOXOME
LOE Approachingdaunorubicin citrate
NDAINJECTIONINJECTABLE, LIPOSOMALPriority Review
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAUNOXOME is a liposomal formulation of daunorubicin citrate, an anthracycline chemotherapy agent delivered via intravenous injection. It is indicated for treatment of advanced HIV-associated Kaposi's sarcoma and certain hematologic malignancies. The liposomal encapsulation enhances drug delivery to tumor tissue while potentially reducing cardiotoxicity compared to conventional daunorubicin.
LOE Approaching
As a mature product approaching loss of exclusivity, the brand team is likely focused on lifecycle management and cost containment rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DAUNOXOME offers limited career upside as a mature, LOE-approaching product with minimal linked job openings. This role is better suited for professionals seeking stable, maintenance-focused positions in established oncology portfolios rather than growth-oriented career advancement.
Oncology Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.